GoodRx stock ticks up after launching weight loss subscription service

Investing.com -- GoodRx Holdings Inc (NASDAQ:GDRX) stock edged up 1.7% in premarket trading Monday after the medication savings platform announced two major initiatives to make GLP-1 weight loss medications more accessible.

The company launched GoodRx for Weight Loss, a telemedicine subscription connecting consumers with licensed healthcare providers for weight management treatment. Additionally, GoodRx partnered with Novo Nordisk to offer an introductory cash price of $199 per month for Ozempic and Wegovy injection pens to first-time GoodRx users.

The new telemedicine service includes virtual consultations, prescription services, and ongoing clinical support. It’s available at an introductory rate of $39 per month through January 2026, with the standard price increasing to $119 beginning February 2026. Medications are priced separately.

"GoodRx is scaling a consumer-first model for affordable GLP-1 treatment," said Wendy Barnes, President and CEO of GoodRx. "We’re committed to connecting consumers with FDA-approved GLP-1 medications backed by science and safety, not compounded alternatives that fall short of those standards."

The Novo Nordisk partnership offers the discounted $199 monthly price for the first two fills of the two lowest doses of Ozempic and Wegovy, followed by an ongoing price of $349 per month for subsequent fills. The offer is valid through March 2026.

GoodRx’s initiatives aim to provide a more affordable path to GLP-1 medications, which have gained popularity for weight management but often come with high price tags without insurance coverage.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.